 | ||||||||||||||||||||||||||||||||||||
 |
PASSION FOR IDEAS |
|||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||
|
|
Molecular PartnersMolecular Partners is developing a novel class of therapeutic proteins, termed DARPins. DARPins equal the target binding properties of antibodies but feature superior stability and are easier to express, thus allowing novel therapeutic approaches. To date, DARPins have been generated against a high number of targets, including cell surface receptors, cytokines, proteases, kinases and viral coat proteins.The company was incorporated in 2004 as a spin-off company of the group of Professor Andreas Plückthun at the University of Zürich. Molecular Partners owns the exclusive commercial rights in DARPins and has a complete freedom to operate in the field.
December 8, 2011 Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins® May 4, 2011 Allergan and Molecular Partners enter into an exclusive license agreement for MP0112 for the treatment of retinal diseases April 28, 2011 Molecular Partners reports positive results from its first clinical studies September 1, 2010 Molecular Partners selected as Technology Pioneer 2011 by the World Economic Forum December 15, 2009 Molecular Partners Secures CHF 46 Million in a Series B Financing January 15, 2008 Molecular Partners AG collaborates with Centocor Research & Development, Inc. August 14, 2007 Molecular Partners Raises 18.5 Mio CHF in Series A Financing |
|
|
|
|||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||
| partner of the European Tech Tour |  |
"The partners have been very supportive of our approach and stepped in to add value when needed. I would strongly recommend them as investors." Didier Cowling, Founder and CEO, Kuros Biosurgery AG |
||||||||||||||||||||||||||||||||||
investments
technology
Sven Lingjaerde
Olivier Valdenaire